Coredio
Coredio provides a highly accurate, non-invasive intra-cardiac monitoring SaaS application designed to improve cardiac patient outcomes. Their technology utilizes AI-assisted digital twin technology and simple wearable sensors to enable first-of-its-kind intracardiac measurements. The platform aids cardiologists in progress tracking and medication titration, significantly reducing unplanned admissions and readmissions. Key features include Central Blood Pressure (cBP), Cardiac Output (CO), Arterial Wall Displacement, and Pulse Transit Time (PTT) monitoring. The process involves a one-time, 20-minute non-invasive calibration, after which the system remains tailored to the individual patient for up to three years, allowing for on-demand monitoring of intra-cardiac BP, cBP, and CO. Coredio has undergone validation at partner hospitals, including Strong Memorial Hospital, showing strong correlation with arterial line BP and echo-based CO, with deviations of less than 5mmHg for Central BP and less than 5% for CO. They are preparing for FDA pre-submission and have ongoing IRB-approved studies.
Coredio
Coredio provides a highly accurate, non-invasive intra-cardiac monitoring SaaS application designed to improve cardiac patient outcomes. Their technology utilizes AI-assisted digital twin technology and simple wearable sensors to enable first-of-its-kind intracardiac measurements. The platform aids cardiologists in progress tracking and medication titration, significantly reducing unplanned admissions and readmissions. Key features include Central Blood Pressure (cBP), Cardiac Output (CO), Arterial Wall Displacement, and Pulse Transit Time (PTT) monitoring. The process involves a one-time, 20-minute non-invasive calibration, after which the system remains tailored to the individual patient for up to three years, allowing for on-demand monitoring of intra-cardiac BP, cBP, and CO. Coredio has undergone validation at partner hospitals, including Strong Memorial Hospital, showing strong correlation with arterial line BP and echo-based CO, with deviations of less than 5mmHg for Central BP and less than 5% for CO. They are preparing for FDA pre-submission and have ongoing IRB-approved studies.